# Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

> **NCT00717236** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 1648 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab pegol (CZP)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00717236
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-03
- **Final completion:** 2011-03
- **Target enrollment:** 1648 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717236, "Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00717236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*